Combining sorafenib and tivantinib, a VEGF inhibitor and a selective MET inhibitor, may provide synergistic or additive anti-tumor activity overcoming the resistance to sorafenib without causing possible off-target side effects of an unselective agent. Here, MET is linked to neoplasm.